Preferencje help
Polish version English version Język
Widoczny [Schowaj] Abstrakt
Liczba wyników

Znaleziono wyników: 13

Liczba wyników na stronie
Pierwsza strona wyników Pięć stron wyników wstecz Poprzednia strona wyników Strona / 1 Następna strona wyników Pięć stron wyników wprzód Ostatnia strona wyników

Wyniki wyszukiwania

Wyszukiwano:
w słowach kluczowych:  chronic hepatitis
help Sortuj według:

help Ogranicz wyniki do:
Pierwsza strona wyników Pięć stron wyników wstecz Poprzednia strona wyników Strona / 1 Następna strona wyników Pięć stron wyników wprzód Ostatnia strona wyników
1

Serum trypsin inhibitory activity and alpha-1-antitrypsin level in liver diseases

100%
Miszczuk-Jamska B., Pajdak W., Barylak H., Odrobina S., Sowa J.
Folia Histochemica et Cytobiologica
|
1986
|
tom 24
|
nr 2
2

Chronic hepatitis C virus infection and the pathogenesis of hepatocellular carcinoma

100%
Feitelson M.
Archivum Immunologiae et Therapiae Experimentalis. Supplement
|
2001
|
tom 49
|
nr 2
65-74
3

Primary hepatocellular carcinoma in patients with chronic hepatitis B virus infection

100%
Kiszkis H.
Archivum Immunologiae et Therapiae Experimentalis
|
1996
|
tom 44
|
nr 5-6
4

Hepatotropic viruses seen by clinicians

100%
Zielinska W., Smiatacz T.
Archivum Immunologiae et Therapiae Experimentalis
|
1996
|
tom 44
|
nr 5-6
5

A competitor DNA template for the molecular quantification of the hepatitis B virus

100%
Sidorkiewicz M., Bzorska A., Jozwiak B., Jablkowski M., Szemraj J., Lewandowska U.
Cellular and Molecular Biology Letters
|
2003
|
tom 08
|
nr 3
The molecular determination of viral load in the serum represents the most valuable prognostic marker of HBV infection. In this paper, a new molecular assay for the quantitative measurement of HBV presence is described. It is based on PCR performing with a HBV-specific competitor DNA template. For the construction of the DNA template, a HBV DNA-originated 436 bp DNA fragment was modified by introducing a 110 bp deletion and cloned into pUC19. The resulting vector serves as the competitor DNA template in the competitive PCR. Post-PCR, the competitor DNA generates an amplified fragment of 306 bp; it could be easily distinguished from the product generated from the viral-originated DNA product (416 bp) when the same primers are used. The quantitative ratio between the two products enables the quantitative determination of viral load. The range of the HB-PCR assay is from 3 x 104 to 6 x 1010 particles/ml. A serum HBV load determination performed by HB-PCR assay indicated a close correlation with the results of the Quantiplex HBV DNA assay (bDNA). The HB-PCR assay is cheap, reliable and easy to use in any laboratory working with PCR methods.
6

Existing and future therapeutic options for hepatitis C virus infection

100%
Bretner M.
Acta Biochimica Polonica
|
2005
|
tom 52
|
nr 1
Hepatitis C virus (HCV) infection is an important cause of chronic hepatitis, cirrhosis, hepatocellular carcinoma and liver failure worldwide. Chronic hepatitis C virus infection is treated with interferon-alpha (IFN-alpha), pegylated interferon-alpha (PEG-IFNalpha) alone or in combination with ribavirin; however, a significant fraction of patients either fail to respond or relapse after cessation of therapy. Efforts to identify and develop highly specific and potent HCV inhibitors have intensified recently. Each of the virally encoded replication enzymes has been a focus of studies as well as viral receptors and the host immune system. This review summarizes recent progress in the search for novel anti-HCV agents.
7

p21/Wafl/Cipl cellular expression in chronic long-lasting hepatitis C: correlation with HCV proteins (C, NS3, NS5A), other cell-cycle related proteins and selected clinical data

80%
Kasprzak A., Adamek A., Przybyszewska W., Olejniczak K., Biczysko W., Mozer-Lisewska I., Zabel M.
Folia Histochemica et Cytobiologica
|
2009
|
tom 47
|
nr 3
8

Observation of the effect of low oral doses of human leukocytic interferon alpha in children with chronic HBV infection and impaired immune response

80%
Ratajczak B.
Archivum Immunologiae et Therapiae Experimentalis
|
1993
|
tom 41
|
nr 3-4
9

Treatment of chronic viral hepatitis type B with oral mucosal administration of natural human interferon alpha lozenges

80%
Caban J., Mossor-Ostrowska J., Zyrkowska-Bieda T., Zejc M., Janas-Skulina U., Ciesla A., Cummins J. M., Georgiades J. A.
Archivum Immunologiae et Therapiae Experimentalis
|
1993
|
tom 41
|
nr 3-4
10

Comparison of the long-term effects of treatment with oral and parenteral interferon alpha in chronic viral hepatitis patients

80%
Zielinska W., Korczak-Rogon A., Paszkiewicz J., Kowalik M., Cummins J. M., Georgiades J. A.
Archivum Immunologiae et Therapiae Experimentalis
|
1996
|
tom 44
|
nr 5-6
11

Hepatitis C virus [HCV] serotype in the asymptomatic HCV-infected patients from selected groups

80%
Pawlowska M., Halota W., Bulik F., Topczewska-Staubach E.
Archivum Immunologiae et Therapiae Experimentalis
|
1997
|
tom 45
|
nr 5-6
12

Wstepna ocena wynikow leczenia chorych z przewleklym zapaleniem watroby HBsAg[+], HBeAg[+] roznymi preparatami interferonu alfa

61%
Zielinska W., Paszkiewicz J., Korczak-Rogon A., Smiatacz T., Michalska Z.
Acta Biologica et Medica
|
1993
|
tom 20
47-60
13

A new alpha-1-antitrypsin phenotype [PiZ Lodz] in Polish population with reduced level in serum

61%
Pilacik B., Kowalska A., Rujner J., Deron Z.
Bulletin of the Polish Academy of Sciences. Biological Sciences
|
1992
|
tom 40
|
nr 3
Pierwsza strona wyników Pięć stron wyników wstecz Poprzednia strona wyników Strona / 1 Następna strona wyników Pięć stron wyników wprzód Ostatnia strona wyników
JavaScript jest wyłączony w Twojej przeglądarce internetowej. Włącz go, a następnie odśwież stronę, aby móc w pełni z niej korzystać.